Faculty Bibliography

The antisialogogue, ammonium glycopyrrolate (Robinul), was used to reduce the salivary flow rate in healthy individuals with normal salivary function to determine whether the dry-mouth symptoms and reduced amounts and patterns of oral mucosal wetness found previously in hyposalivators could be induced by this means. After baseline measurements, the drug was given to 10 healthy volunteers and their resting whole-saliva flow rate was measured at 0, 15, 60, 105 and 150 min thereafter. At the same times, the thickness of the layer of residual mucosal saliva (a measure of residual mucosal wetness) at each of 22 intraoral sites was also determined. The saliva flow rate fell from a mean of 0.45 +/- 0.07 ml/min to a mean of 0.05 +/- 0.02 ml/mm by 1 h and slowly thereafter to a mean of 0.02 +/- 0.01 to 0.03 +/- 0.01 ml/min for the remainder of the experiment. Onset of dryness symptoms was observed approx. 30 min after giving the drug. Simultaneously, the residual saliva at each of the 22 sites teted decreased to a thickness level previously found in patients with hyposalivation and who exhibited an intense feeling of dry mouth. Despite these decreases in thickness, the pattern of residual mucosal wetness throughout the mouth remained more or less unchanged. As in earlier studies, wetness was least on the hard palate and highest on the posterior dorsum of the tongue. An altered taste of the residual saliva in the mouth and an increased feeling of roughness as the tongue was passed over labial and buccal mucosal surfaces were noted. The amount of gingival crevicular fluid (GCF) in 12 gingival sites in each of the participants was also measured. Unlike the reduction in salivary flow, changes in GCF over the 150 min of the study were negligible. From this it was concluded that GCF could contribute much more to the oral fluids in dry-mouth than in normal individuals, especially when there is greater gingival inflammation

Dentinal hypersensitivity is a common dental problem without a satisfactory solution. Most therapies have focused on either trying to block the stimulation of dentinal nerves or on sealing open dentinal tubules. This study evaluated, in a double blind clinical trial, the effect of Enamelon, a dentifrice containing sodium fluoride, calcium salts and phosphate salts (calcium separated from the phosphate and fluoride by a plastic divider in the tube to prevent interaction) on dentinal hypersensitivity over an 8-week period. A conventional OTC dentifrice containing NaF without calcium and phosphate enhancement served as the control. A third dentifrice, containing sodium monofluorophosphate enhanced by calcium and phosphate salts, was also tested. Based upon subjective anecdotal information, net numbers of sensitive teeth which became non-sensitive, and a logit analysis of the change in the proportion of sensitive teeth over the study time period, Enamelon was the most effective product, and the OTC control the least effective

After a person swallows, a film of residual saliva covers the oral hard- and soft-tissue surfaces. Here, the thickness of this film was measured at 11 selected mucosal surfaces on each side of the mouth (22 sites total) in two groups of dry-mouth and one group of normal individuals. Each group contained 25 individuals; one of the dry-mouth groups had resting flow rates < or = 0.1 ml/min while the other and the normal had flow rates above that. Residual saliva thickness was determined by placing frying-pan-shaped filter-paper strips (Sialopaper) against the mucosa at each site for 5 s and measuring the saliva volume collected with a modified Periotron 6000 micro-moisture meter; the thickness was then calculated by dividing the collected saliva volume by the strip area. The two groups with dry-mouth symptoms had mean resting (unstimulated) saliva flow rates of 0.04 and 0.19 ml/min and mean mucosal saliva thicknesses of 22.4 and 27.8 microns, respectively. The control group had a higher mean saliva flow rate of 0.39 ml/min and mucosal saliva thickness of 41.8 microns. As was observed in a previous study on normosalivators, the various sites had a characteristic pattern of wetness, with the hard palate and lips the least moist regions. In this study, these observations, were also true in the two dry-mouth groups. Lower resting saliva flow rates were associated with lower mucosal thickness of saliva and with dryness symptoms becoming evident when hyposalivation was below about 0.1-0.2 ml/min. The characteristic pattern of mucosal wetness was not affected by saliva flow rate. As saliva readily collects in the floor of the mouth and is then spread over other mucosal surfaces upon swallowing, it was suggested that hyposalivation could also lead to the dryness symptoms because there was not enough saliva to cover the various oral surfaces, especially the palate and the lips. In this regard, a critical level of moisture was proposed as necessary to protect vulnerable mucosal surfaces from becoming dry. Lower resting saliva flow rates and correspondingly lower mucosal wetness were also associated with a more acidic salivary pH, which was shown earlier to be associated with lower dental plaque pH

Intraoral lidocaine patches have recently been approved by the US Food and Drug Administration for the production of topical anesthesia before superficial dental procedures and for the reduction of pain associated with local anesthetic injections. The results of this 5-center clinical study showed that lidocaine patches were significantly more efficacious than matching placebo patches in reducing the pain associated with 25-gauge needle insertions to the level of bone in the maxillary premolar region. Anesthetic onset occurred within 5 minutes and was present for the entire 15-minute period that the patches were in contact with the oral mucosa. In addition, the patches were safe and well tolerated by study participants. Other potential clinical applications of this novel delivery system are also discussed in this article